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Background: Apolipoprotein-E (apoE) is one of the metabolically active apoproteins and plays an important role in
lipid metabolism. However, there are no data on levels of apoE in residents of the North in spite of the fact that
specific features of lipid metabolism in the northerners are described. The present work was designed to study
plasma levels of apoE in residents of the European North of Russia.
Methods: A total of 937 native residents of the European North of Russia (463 men and 474 women) aged 13–60 years
were included in the study. ApoE concentrations in the blood plasma were measured by immunoturbidimetric
method.
Results: Plasma levels of apoE in residents of the European North of Russia were low. ApoE concentrations below
the defined normal values were detected in 57.0% of the men and in 59.2% of the women. The mean plasma
levels of apoE did not significantly differ in men and women (2.80 mg/dl vs 2.87 mg/dl). Plasma apoE
concentrations in residents of the European North of Russia changed with age. Plasma levels of apoE decreased
from 13 to 21 years in men and from 13 to 35 years in women and then increased in both sexes (p < 0.001).
Conclusion: The limits of variation of plasma apoE levels in residents of the European North of Russia shift
towards lower values. Plasma levels of apoE below normal values were observed in approximately half of
investigation subjects.
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Apolipoprotein-E (apoE) is a monomeric glycoprotein
with 299 amino acid residues and 34 kDa molecular mass
[1]. The protein is a structural and functional constituent
of plasma chylomicrons and very low density lipopro-
teins (VLDL) and their lipolytic degradation products
(i.e. chylomicron remnants and intermediate density lipo-
proteins). ApoE is also found in some subfractions of high
density lipoproteins (HDL) [2-4]. This apolipoprotein is
synthesized in liver and extrahepatic tissues (brain,
kidneys, adrenal glands, spleen, muscles, skin, macro-
phages, etc.). Plasma apoE is largely liver-derived [5,6].
ApoE plays important role in lipid metabolism. The
main function of apoE is to regulate uptake of lipopro-
teins from the circulation by receptor-mediated endo-
cytosis [4,7]. ApoE also participates in the synthesis of* Correspondence: amkaneva@mail.ru
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reproduction in any medium, provided the orsome lipoproteins, in the transport and redistribution of
lipids among various tissues including the cholesterol
transport from peripheral tissues in the liver, in the
reparation of nervous cells and the vascular wall. More-
over, this protein has been shown in vitro to have anti-
oxidant and anti-inflammatory properties [5,8-16].
Considerable influence of apoE on the lipid profile has
been shown in studies on apoE-deficient mice and trans-
genic rabbits expressing high levels of apoE. ApoE-
deficient mice have extremely high lipid levels and
massive amounts of cholesterol-rich β-VLDL, resulting
in development of severe atherosclerotic lesions even on
a normal diet [17-19]. On the other hand, high plasma
levels of apoE may also be associated with increased risk
of dyslipidemia. It is supposed that high levels of apoE
increase atherosclerosis risk by stimulating hepatic
VLDL production and inhibiting VLDL lipolysis. Thus
there is an optimal range of plasma apoE levels that is
maximally beneficial, and that levels above or below thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rosis [5,20]. In normolipidemic subjects, normal values
of plasma concentration of apoE are 3-7 mg/dl [4].
At present time, major attention is given to the study-
ing of polymorphism of the аpоЕ gene. There are three
common alleles of the apoE gene (ε2, ε3, ε4) coding
three isoforms (E2, E3, E4). Population studies have
shown that apoE isoforms influence lipid and apolipo-
protein levels and are important determinants of risk for
the development of cardiovascular diseases [21-24].
Plasma apoE concentration is usually not taken into
account in similar studies. However, it is known that
levels of apoE can change or even mask the apoE gene
polymorphism effects on lipid parameters [25,26]. Hence
studying the apoE gene polymorphism effects on plasma
lipid levels without taking into account apoE concentra-
tion could lead to confounding results. Meanwhile, influ-
ence of the apoE gene polymorphism on apoE levels was
not always found [27,28]. Besides, the ε3 allele in all
populations is the most frequent, with a range of 67-80%
[29]. So we consider that the intent attention to the
apoE gene polymorphism and insufficient interest in
levels of this protein might not be correct.
The data on biological variations of plasma apoE levels
are contradictory [3,25,30-36]. There are not much data
on concentration and influence of apoE on lipid profile
in residents of the North in spite of the fact that specific




Subjects were apparently healthy residents of the European
North of Russia (natives from five areas of Komi Republic
located between 62° and 65° North latitude, 68% of
Russians and 32% of Komi). The total number of sub-
jects participating was 937; consisting of 463 men and
474 women aged between 13-60 years. The subjects of
both sexes were divided into the following age groups:
13-15 years (71 boys and 80 girls), 17-21 years (97 men
and 101 women), 22-35 years (101 men and 107 women),
36-45 years (90 men and 85 women), and 46-60 years
(104 men and 101 women).
Participants were excluded from the study by the
following criteria: (i) a body mass index (BMI) of 30 or
greater (BMI = weight in kilograms divided by height in
meters squared); (ii) total cholesterol concentration
above 5.5 mmol/l; (iii) triglycerides concentration above
1.8 mmol/l; (iv) glucose concentration above 6.0 mmol/l.
All participants were considered as being free from
serious and chronic illnesses at the time of the recruit-
ment. Each subject gave written informed consent for
participating in the study, which was approved by the
ethics committee of Institute of Physiology, KomiScience Center, Ural Branch of Russian Academy of
Sciences.
A single blood sample of 5 ml was taken by rapid
venipuncture with minimum stasis in the morning at
9 am after an overnight fast of 12-13 h. The samples were
collected into vacutainers (Becton Dickinson BP). Blood
samples were centrifuged and plasma was placed into
eppendorf microcentrifuge tubes and was stored at -20°C
until analysis.
ApoE measurements
ApoE concentration in the blood plasma was measured by
immunoturbidimetric method using a kit from «Chronolab»
(Switzerland, Cat. No 101-0550). The samples were analyzed
immediately after thawing at 37°C in thermostatic bath.
Measurement of each sample was carried out in duplicate,
and the mean was calculated. Absorbance of all samples
was measured on the Power Wave-200 automated spectro-
photometer (Bio-Tek Instruments, USA) at 340 nm.
Analytical procedures
Total cholesterol, triglycerides, HDL-cholesterol and
glucose concentrations in the blood plasma were deter-
mined using enzymatic methods on the Power Wave-200
automated spectrophotometer (Bio-Tek Instruments,
USA) with commercially available kits («Chronolab»,
Switzerland).
Statistical analysis
Statistical analysis was performed with Statistica 6.0
(Statsoft, Tulsa, USA). Continuous variables are
presented as median and interquartile range (25th and
75th percentiles), and qualitative variables are expressed
as relative frequencies. Continuous data were analyzed
using the Mann-Whitney (for two groups) and the
Kruskal-Wallis tests (for three and more groups). Where
the Kruskal-Wallis test revealed significant effect, the
Mann-Whitney test with Bonferroni correction for mul-
tiple comparisons was used to discern differences between
groups. The chi-squared test was used for comparison of
qualitative variables. Correlations between indices were
assessed using the Spearman rank correlation. A value of
p < 0.05 was accepted as statistically significant.
Results
Table 1 gives the baseline characteristics of the study
subjects. All subjects had BMI, lipids and glucose levels
within the laboratory normal range by virtue of the
exclusion criteria. These parameters increased with age
in both men and women (p < 0.001).
Plasma concentrations of apoE in residents of the
European North of Russia are presented in Table 2. In
residents of the European North of Russia, there were
no significant differences in plasma levels of apoE
Table 1 The baseline characteristics in residents of the European North of Russia
N Body mass index, kg/m2 Total cholesterol, mmol/l Triglycerides, mmol/l HDL-cholesterol, mmol/l Glucose, mmol/l
Men, n = 463
1 group 71 19.2 3.75 0.83 1.06 3.83
13-15 years (17.4; 21.3) (3.33; 4.20) (0.69; 1.02) (0.91; 1.27) (3.38; 4.63)
2 group 97 19.4 3.55 0.93 0.99 3.99
17-21 years (18.1; 20.9) (2.63; 4.09) (0.80; 1.10) (0.86; 1.39) (3.48: 4.60)
3 group 101 25.1 4.05 1.16 1.29 4.41
22-35 years (23.1; 26.9) (3.53; 4.56) (0.92; 1.33) (0.88; 1.51) (4.04; 4.84)
4 group 90 25.4 4.46 1.13 1.35 4.49
36-45 years (23.0; 27.5) (3.89; 4.86) (0.93; 1.36) (1.16; 1.62) (4.03; 4.88)
5 group 104 26.7 4.31 1.02 1.42 4.56
46-60 years (24.3; 28.4) (3.86; 4.75) (0.86; 1.20) (1.12; 1.62) (4.09; 5.08)
p value <0.001 <0.001 <0.001 <0.001 <0.001
Women, n = 474
1 group 80 20.2 3.65 0.84 1.06 3.67
13-15 years (18.4; 22.1) (3.27; 4.26) (0.70; 1.05) (0.95; 1.30) (3.17; 4.34)
2 group 101 20.1 3.59 0.94 1.13 3.86
17-21 years (18.0; 22.1) (3.11; 4.13) (0.81; 1.07) (0.96; 1.49) (3.42; 4.27)
3 group 107 20.8 3.88 0.81 1.47 3.93
22-35 years (19.1; 23.5) (3.58; 4.33) (0.69; 0.98) (1.05; 1.79) (3.43; 4.55)
4 group 85 23.9 4.29 0.87 1.60 4.13
36-45 years (21.3; 27.6) (3.84; 4.68) (0.68; 1.08) (1.13; 1.81) (3.73; 4.74)
5 group 101 26.9 4.44 0.94 1.62 4.30
46-60 years (25.4; 27.9) (4.03; 4.83) (0.80; 1.14) (1.41; 1.88) (3.92; 4.85)
p value <0.001 <0.001 <0.001 <0.001 <0.001
Data are expressed as median (interquartile range).
p value; Statistical significance of differences between age groups was estimated using the Kruskal-Wallis test.
Table 2 Plasma apolipoprotein-E levels (mg/dl) in residents of the European North of Russia by sex and age
Age group Men Women p1 value
Total 2.80 (1.97; 3.72) 2.87 (2.07; 3.65) 0.652
13-60 years n = 463 n = 474
1 group 2.70 (1.91; 3.84) 2.96 (1.94; 3.68) 0.886
13-15 years n = 71 n = 80
2 group 2.19 (1.57; 3.00) *1-2 2.52 (1.64; 3.29) 0.147
17-21 years n = 97 n = 101
3 group 2.35 (1.66; 3.08) 2.45 (1.87; 3.25) 0.262
22-35 years n = 101 n = 107
4 group 2.98 (2.23; 3.73) **2-4; 3-4 3.15 (2.32; 3.86) **2-4; 3-4 0.309
36-45 years n = 90 n = 85
5 group 3.50 (2.88; 4.07) *1-5; **2-5; 3-5 3.11 (2.39; 3.95) **2-5; 3-5 0.094
46-60 years n = 104 n = 101
p2 value <0.001 <0.001
Data are expressed as median (interquartile range).
p1 value; Statistical significance of differences between men and women was estimated using the Mann-Whitney test.
p2 value; Statistical significance of differences between age groups was estimated using the Kruskal-Wallis test. Differences between age groups are statistically
significant at: * - p < 0.05; ** - p < 0.01 (the Mann-Whitney test with Bonferroni correction).
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Table 4 Correlation coefficients of age and plasma
apolipoprotein-E levels with other covariates
Men (n = 463) Women (n = 474)
Age apoE Age apoE
Body mass index 0.71*** 0.05 0.55*** −0.03
Total cholesterol 0.38*** 0.24*** 0.40*** 0.15***
Triglycerides 0.33*** −0.03 0.13*** −0.10*
HDL-cholesterol 0.30*** 0.04 0.42*** 0.05
Glucose 0.33*** 0.07 0.30*** 0.03
apoE 0.26*** - 0.18*** -
Correlations are statistically significant at: * - p < 0.05; *** - p < 0.001.
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that the mean plasma apoE levels were 2.80 mg/dl in men
and 2.87 mg/dl in women (Table 2). The analysis of indi-
vidual data has shown that apoE concentrations below
normal values were observed in 57.0% of the men and
59.2% of the women. The maximum deviation of plasma
apoE levels from the lower limit of normal values reached
78.3% in men and 86.7% in women. There were no sub-
jects with plasma levels of apoE above normal values. No
significant differences in percentage of subjects with low
and normal values of apoE between men and women were
detected (χ2 = 0.002; p = 0.962).
Plasma levels of apoE in residents of the European
North of Russia changed with age (Table 2). Plasma
apoE concentrations were higher in the adolescent group
(13-15 years) compared with subjects 17-35 years old.
Men and women aged 17-21 years had apoE levels on
19% (p = 0.040) and 15% (p = 0.305) less than the adoles-
cents. The significant increase of plasma apoE concen-
trations in residents of the European North of Russia
was observed after age 35. The age-related increase of
plasma apoE levels in men was simultaneously accom-
panied by significant decrease of number of subjects with
apoE concentrations below normal values (χ2 = 17.07;
p = 0.002) (Table 3). The lowest percent of subjects
with apoE levels below normal values was observed in
the group after 45 years. In women the number of
subjects with low values of apoE also tended to de-
crease with age but these changes were statistically in-
significant (χ2 = 7.01; р = 0.135).
Strong influence of age on BMI, lipids and glucose levels
(p < 0.001) was confirmed by means of the Spearman’s
rank correlation (Table 4). Meanwhile, apoE was corre-
lated only with total cholesterol (rs = 0.24; p < 0.001) in
men and with total cholesterol (rs = 0.15; p < 0.001) and
triglycerides (rs = -0.10; p = 0.037) in women. No signifi-
cant correlation between plasma apoE levels and BMI was
observed. These data indicate that age-related changes ofTable 3 The percentage of subjects with values of
apolipoprotein-E below normal values in the age groups
of residents of the European North of Russia
Age group Men (%) Women (%)
Total 13-60 years 57.0 59.2
13-15 years 57.7 52.2
17-21 years 74.2 68.3
22-35 years 73.3 71.0
36-45 years 52.2 42.4
46-60 years 28.8 47.5
p value 0.002 0.135
Data are presented as percentage.
p value; Statistical significance of differences between age groups was
determined by Chi-square test.apoE concentrations in residents of the European North of
Russia were associated to a certain extent with alterations
of lipid profile whereas BMI did not influence apoE levels.
Discussion
Our results demonstrated that plasma apoE levels were
not different between men and women. This fact is con-
sistent with data from other studies [30-32]. At the same
time, other authors have revealed presence of sex-related
differences in apoE concentrations in humans. In some
studies it has been demonstrated that apoE concentra-
tions were higher in women, in others, apoE concentra-
tions were higher in men [3,33,34]. It is suggested that
sex hormones might cause the differences in apoE con-
centration between men and women [25]. Sex hormones
are known to have multiple effects on lipid metabolism
[39]. In particular, it has been determined that adminis-
tration of estradiol to castrated male rats increased the
level of apoE in lipoprotein fractions, whereas adminis-
tration of testosterone to castrated female rats had the
opposite effect [40]. Thus, it is possible to suppose that
the hormonal status does not influence plasma apoE
levels in residents of the European North of Russia or
this effect is masked by other factors.
Age is supposed to be a significant factor for apoE
level variation. Results of studies about age influence on
apoE concentrations are conflicting. Several studies have
demonstrated that apoE concentrations in blood de-
crease with age [41]. At the same time, there are data
showing increase of apoE levels with age [33]. More de-
tailed studies have shown that age ambiguously influ-
ences apoE concentrations in the process of maturing.
Overall, apoE levels in blood decrease from birth and
childhood until age 20-30 years. After age 30, apoE con-
centrations increase until age 60 years. The highest apoE
concentrations are found between 50 and 60 years. The
decrease of apoE levels was revealed after 60 years. Sub-
jects older than 80 years have lower apoE concentrations
(on 25%) than the 50-60 year-old group [23, 31, 34,].
The age dynamics of plasma apoE levels in residents of
the European North of Russia revealed by us correspond
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described above. In residents of the European North of
Russia, plasma levels of apoE decreased from 13 to 21 -
years in men and from 13 to 35 years in women and
then increased in both sexes. The observed increase of
apoE levels with age was probably associated with age-
related changes of lipid metabolism. The increase of
total cholesterol and triglycerides concentrations, the
transformation of lipoprotein profile, the decrease of
synthesis and number of apoB,E-receptors, the lowering
of lipolitic enzymes activity and fatty acids oxidation
intensity are known to be main age-related changes of
lipid metabolism [42,43]. In our study, significant posi-
tive correlation between apoE and total cholesterol levels
was observed in both men and women. This shows that
age dynamics of plasma apoE levels in residents of the
European North of Russia was primarily due to changes
of total cholesterol concentration. Thus the increase of
plasma apoE levels in the elder age groups in our study
can be considered as a compensation of age-related
changes in lipid metabolism.
In comparison with other studies, apoE levels in resi-
dents of the European North of Russia were low. In view
of the variety of methods and calibrators used for apoE
measurements it is difficult to compare the results
received in our study with data of the literature. The
apoE values reported in different studies vary widely
[23]. In general, the mean values for apoE obtained by
radioimmunoassay ranged from 3.6 to 6.0 mg/dl [33,44].
However, some authors reported higher results [45,46].
For enzyme-linked immunosorbent assay the average
values of apoE found by different authors can be divided
into two groups: between 2.0 and 4.0 mg/dl [47,48] and be-
tween 5.0 and 9.5 mg/dl [49,50]. Electroimmunoassay gives
mostly the highest values, ranging from 6.7 to 11.9 mg/dl
[51,52]. The reported mean concentrations of serum
(plasma) apoE measured by immunoturbidimetry in control
subjects are between 3.5 and 4.9 mg/dl [23,25,36].
The most suitable and interesting results were received
in a large international study where a comparative esti-
mation of apoE levels in blood among subjects from six
countries of the Europe has been carried out [25,35].
According to results of this study, there is a north-south
increasing gradient of apoE concentrations. The lowest
apoE levels were observed in residents of Finland. ApoE
concentrations (3.69 mg/dl in men and 3.56 mg/dl in
women) in blood in residents of Finland (45-64 years
old) were comparable to our results obtained for age-
matched residents of the European North of Russia. In
opinion of some authors, apoE concentration in blood is
defined by the hepatic apoE production rate, not by
apoE residence time in blood [20,53]. Thus, it is possible
to assume that residents of the European North of
Russia have a low apoE production.The lower plasma levels of apoE in residents of the
European North of Russia can be caused by features of the
lipid metabolism. Lipid metabolism in residents of the
North is characterized by a number of specific features
due to the increased role of lipids in the energy metabol-
ism of the human organism and specific transformations
of some metabolic pathways. The alterations of energy
metabolism in residents of high latitudes can be character-
ized as «the change-over from carbohydrate-type metabol-
ism to the lipid one» [54]. One of the most illustrative
manifestations of this phenomenon is the increase of
the levels of triglycerides and VLDL in the blood of
northerners. Thus low values of apoE in residents of
the European North of Russia can be considered as
adaptive changes providing metabolic transformation to
activate lipid energy.
Conclusion
A shift in plasma apoE levels towards lower values is
characteristic for residents of the European North of
Russia. Plasma apoE levels below the normal values have
been observed in approximately half of the examined
northerners. The low values of apoE in residents of the
European North of Russia can be connected with the
specific features of lipid metabolism. Thus results of this
study provide additional evidence of adaptive changes of
lipid metabolism in residents of the North. The received
values of apoE in residents of the European North of
Russia should be considered in studies of lipid metabol-
ism in the northerners.
Abbreviations
apoE: Apolipoprotein-E; BMI: Body mass index; VLDL: Very low density
lipoproteins; HDL: High density lipoproteins.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributors
ERB and JOO were responsible for the initial conception and design of the
study. NNP coordinated the blood samples collection and performed
analyses. AMK contributed to the statistical analysis and interpretation data
and wrote the first draft of the paper. All authors contributed to the critically
revision of the article and approved the final published version to be
published. All authors read and approved the final manuscript.
Author details
1Institute of Physiology, Komi Science Center, Ural Branch of Russian
Academy of Sciences, Pervomaiskaya av. 50, Syktyvkar 167982, Russia.
2Faculty of Health Sciences, University of Tromso, Tromso NO-9037Norge,
Norway.
Received: 21 January 2013 Accepted: 21 March 2013
Published: 27 March 2013
References
1. Rall SC, Weisgraber KH, Mahley RW: Human apolipoprotein E. The
complete amino acid sequence. J Biol Chem 1982, 257:4171–4178.
2. Shore B, Shore V: Heterogeneity of human plasma very low density
lipoproteins. Biochemistry 1973, 12:502–507.
3. Havel RJ, Kotite L, Vigne JL, Kane JP, Tun P, Phillips N, Chen GC:
Radioimmunoassay of human arginine-rich apolipoprotein,
Kaneva et al. Lipids in Health and Disease 2013, 12:43 Page 6 of 7
http://www.lipidworld.com/content/12/1/43apolipoprotein E. Concentration in blood plasma and lipoproteins as
affected by apoprotein E-3 deficiency. J Clin Invest 1980, 66:1357–1362.
4. Mahley RW, Innerarite TL, Rall SC, Weisgraber KH: Plasma lipoproteins:
apolipoprotein structure and function. J Lipid Res 1984, 25:1277–1294.
5. Mahley RW: Apolipoprotein E: cholesterol transport protein with
expanding role in cell biology. Science 1988, 240:622–630.
6. Williams DL, Dowson PA, Newman TC, Rudel LL: Synthesis of
apolipoprotein by peripheral tissues. Ann. NY Acad Sci 1985, 455:222–229.
7. Funke H, Boyles J, Weisgraber KH, Ludwig EH, Hui DY, Mahley RW: Uptake
of apolipoprotein E-containing high density lipoproteins by hepatic
parenchymal cells. Arteriosclerosis 1984, 4:452–461.
8. Koo C, Innerarity TL, Mahley RW: Obligatory role of cholesterol and
apolipoprotein E in the formation of large cholesterol-enriched and
receptor-active high density lipoproteins. J Biol Chem 1985, 260:11934–11943.
9. Eisenberg S: High density lipoprotein metabolism. J Lipid Res 1984,
25:1017–1058.
10. Vogel T, Guo NH, Guy R, Drezlich N, Krutzsch HC, Blake DA, Panet A, Roberts
DD: Apolipoprotein E: a potent inhibitor of endothelial and tumor cell
proliferation. J Cell Biochem 1994, 54:299–308.
11. Hayek T, Oiknine J, Brook JC, Aviram M: Increased plasma and lipoprotein
lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun
1994, 201:1567–1574.
12. Mabile L, Lefebvre C, Lavigne J, Boulet L, Davignon J, Lussier-Cacan S,
Bernier L: Secreted apolipoprotein E reduces macrophage-mediated LDL
oxidation in an isoform-dependent way. J Cellular Biochemistry 2003,
90:766–776.
13. Pham T, Kodyawala A, Hui DY: The receptor binding domain of
apolipoprotein E is responsible for its antioxidant activity. Biochemistry
2005, 44:7577–7582.
14. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA: Apolipoprotein E
inhibition of proliferation of mitogen-activated T lymphocytes:
production of interleukin 2 with reduced biological activity. Cell Immunol
1994, 159:124–139.
15. Ali K, Middleton M, Pure E, Rader DJ: Apolipoprotein E suppresses the
type I inflammatory response in vivo. Circ Res 2005, 97:922–927.
16. Boiko ER, Kaneva AM: Apoprotein E and its availability in clinical
physiology. Usp Fiziol Nauk 2009, 40:3–15.
17. Hofker MH, van Vlijmen BJ, Havekes LM: Transgenic mouse models to
study the role of APOE in hyperlipidemia and atherosclerosis.
Atherosclerosis 1998, 13:1–11.
18. Bock HH, Herz J, May P: Conditional animal models for the study of lipid
metabolism and lipid disorders. Handb Exp Pharmacol 2007, 178:407–439.
19. Huang Y, Ji Z-S, Brecht WJ, Rall SC, Taylor JM, Mahley RW: Overexpression
of apolipoprotein E3 in transgenic rabbits causes combined
hyperlipidemia by stimulating hepatic VLDL production and impairing
VLDL lipolysis. Arterioscler Thromb Vasc Biol 1999, 19:2952–2959.
20. Mahley RW, Huang Y, Rall SC: Pathogenesis of type III
hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries,
and paradoxes. J Lipid Res 1999, 40:1933–1949.
21. Utermann G, Hees M, Steinmetz A: Polymorphism of apolipoprotein E and
occurrence of dysbetalipoproteinaemia in man. Nature 1977, 269:604–607.
22. Breslow JL: Apolipoprotein genetic variation and human disease.
Physiol Rev 1988, 68:85–132.
23. Siest G, Pillot T, Regis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM,
Visvikis S: Apolipoprotein E: an important gene and protein to follow in
laboratory medicine. Clin Сhem 1995, 41:1068–1086.
24. Mahley RW, Rall SC: Apolipoprotein E: far more than a lipid transport
protein. Annu Rev Genomics Hum Genet 2000, 1:507–537.
25. Haddy N, De Bacquer D, Chemaly MM, Maurice M, Ehnholm C, Evans A,
Sans S, Martins MC, De Backer G, Siest G, Visvikis S: The importance of
plasma apolipoprotein E concentration in addition to its common
polymorphism on inter-individual variation in lipid levels: results from
Apo Europe. Europ J Hum Genetics 2002, 10:841–850.
26. Liberopoulos EN, Miltiadous GA, Cariolou M, Tselepis AD, Siamopoulos KC,
Elisaf MS: The influence of serum apolipoprotein E concentration and
polymorphism on serum lipid parameters in hemodialysis patients.
Am J Kidney Dis 2004, 442:300–308.
27. Kobori S, Nakamura N, Uzawa H, Shichiri M: Influence of apolipoprotein E
polymorphism on plasma lipid and apolipoprotein levels, and clinical
characteristics of type III hyperlipoproteinemia due to apolipoprotein E
phenotype E2/2 in Japan. Atherosclerosis 1988, 69:81–88.28. Hanis CL, Hewett-Emmett D, Douglas TC, Bertin TK, Schull WJ: Effects of the
apolipoprotein E polymorphism on levels of lipids, lipoproteins, and
apolipoproteins among Mexican-Americans in Starr County, Texas.
Arterioscler Thromb 1991, 11:362–370.
29. Gerdes LU, Klausen IC, Sihm I, Faergeman O: Apolipoprotein E
polymorphism in a Danish population compared to findings in 45 other
study populations around the world. Genet Epidemiol 1992, 9:155–167.
30. Gregg RE, Zech LA, Schaefer EJ, Brewer HB: Apolipoprotein E metabolism
in normolipoproteinemic human subjects. J Lipid Res 1984, 25:1167–1176.
31. Au YPT, Bren ND, Kottke BA: A rapid apolipoprotein E radioimmunoassay
using solid-phase Staphylococcus protein. Use of pooled plasma as a
secondary standard. Biochem Biophys Res Commun 1986, 138:455–462.
32. Liu M, Liu B: Serum apolipoprotein E levels in 238 healthy adults and 161
hyperlipidemic subjects in Chengdu area. Hua Xi Yi Ke Da Xue Xue Bao
1992, 23:261–263.
33. Phillips NR, Havel RJ, Kane JP: Sex-related differences in the
concentrations of apolipoprotein E in human blood plasma and plasma
lipoproteins. J Lipid Res 1983, 24:1525–1531.
34. Noma A, Hata Y, Goto Y: Quantitation of serum apolipoprotein A-I, A-II, B, C-II,
C-III and E in healthy Japanese by turbidimetric immunoassay: reference
values, and age- and sex-related differences. Clin Chim Acta 1991, 199:147–157.
35. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A,
Kafatos A, Martins MC, Sans S, Sass C, Visvikis S, De Backer G, Siest G:
Apolipoprotein E serum concentration and polymorphism in six European
countries: the ApoEurope project. Atherosclerosis 2000, 152:475–488.
36. Vincent-Viry M, Schiele F, Gueguen R, Bohnet K, Visvikis S, Siest G: Biological
variations and genetic reference values for apolipoprotein E serum
concentrations: results from the STANISLAS cohort study. Clin Chem 1998,
44:957–965.
37. Bang HO, Dyerberg J, Nielsen AB: Plasma lipid and lipoprotein pattern in
Greenlandic West-coast Eskimos. Lancet 1971, 1:1143–1145.
38. Boiko ER, Tkachev AV: The characteristics of lipid metabolism in
permanent residents of the North. Fiziol Cheloveka 1994, 20:136–142.
39. Wang X, Magkos F, Mittendorfer B: Sex differences in lipid and lipoprotein
metabolism: it's not just about sex hormones. J Clin Endocrinol Metab
2011, 96:885–893.
40. Patsch W, Kim K, Wiest W, Schonfeld G: Effects of sex hormones on rat
lipoproteins. Endocrinology 1980, 107:1085–1094.
41. Srinivasan SR, Wattigney W, Webber LS, Berenson GS: Serum
apolipoprotein E in children and adolescents: the Bogalusa Heart Study.
Metabolism 1989, 38:1173–1178.
42. Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS,
Schaefer EJ: Impact of age on the metabolism of VLDL, IDL, and LDL
apolipoprotein B-100 in men. J Lipid Res 1995, 36:1155–1167.
43. Toth MJ, Tchernof A: Lipid metabolism in the elderly. Eur J Clin Nutr 2000,
54:121–125.
44. Blum CB, Aron L, Sciacca R: Radioimmunoassay studies of human
apolipoprotein E. J Chin Invest 1980, 66:1240–1250.
45. Yamada N, Murase T, Akanuma Y, Itakura H, Kosaka K: Plasma
apolipoprotein E levels in hypertriglyceridemia. Horm Metab Res 1982,
14:303–306.
46. Holmquist L: Quantitation of human serum very low density
apolipoproteins C-I, C-II, C-III and E by enzyme immunoassay. J Immunol
Methods 1980, 34:243–251.
47. Alsayed N, Rebourcet R, Chapman J: Concentrations of apoproteins CII,
CIII, and E in total serum and in the apoprotein B-containing
lipoproteins, determined by a new enzyme-linked immunosorbent
assay. Clin Chem 1990, 36:2047–2052.
48. Bury J, Vercaemst R, Rosseneu M, Belpaire F: Apolipoprotein E quantified
by enzyme-linked immunosorbent assay. Clin Chem 1986, 32:265–270.
49. Gracia V, Fiol C, Hurtado I, Pinto X, Argimon JM, Castineiras MJ: An enzyme-
linked immunosorbent assay method to measure human apolipoprotein
E levels using commercially available reagents: effect of apolipoprotein E
polymorphism on serum apolipoprotein E concentration. Anal Biochem
1994, 223:212–217.
50. Carlsson J, Armstrong VW, Reiber H, Felgenhauer K, Seidel D: Clinical
relevance of the quantification of apolipoprotein E in cerebrospinal fluid.
Clin Chim Acta 1991, 196:167–176.
51. Avogaro P, Bittolo Bon G, Gazzolato G, Pontoglio E, Kostner GM:
Distribution and concentration of apolipoprotein E in high and low
density lipoproteins. Ric Clin Lab 1983, 13:431–436.
Kaneva et al. Lipids in Health and Disease 2013, 12:43 Page 7 of 7
http://www.lipidworld.com/content/12/1/4352. Bittolo Bon G, Cazzolato G, Saccardi M, Kostner GM, Avogaro P: Total
plasma apo E and high density lipoprotein apo E in survivors of
myocardial infarction. Atherosclerosis 1984, 53:69–75.
53. Millar JS, Mayer J, Lichtenstein AH, Dolnikowski GG, Ordovas JM, Schaefer EJ:
Apo E and apo B100 kinetics in triglyceride-rich lipoproteins and their
role in LDL production. Circulation 1998, 98:305–306.
54. Panin LE: Human homeostasis in high-latitude environment. Alaska Med
2007, 49:25–28.
doi:10.1186/1476-511X-12-43
Cite this article as: Kaneva et al.: Plasma levels of apolipoprotein-E in
residents of the European North of Russia. Lipids in Health and Disease
2013 12:43.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
